Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Lademirsen

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi walks away from Regulus' kidney disease therapy
    Sanofi walks away from Regulus' kidney disease therapy

    19 Jul 2022

    // Annalee Armstrong FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/sanofi-walks-away-kidney-disease-therapy-leaving-25m-milestones-out-reach-regulus

    Annalee Armstrong FIERCEBIOTECH
    19 Jul 2022
    Share Share
    Regulus Completes Enrollment in Phase 2 Trial of Lademirsen for Alport Syndrome
    Regulus Completes Enrollment in Phase 2 Trial of Lademirsen for Alport Syndrome

    24 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-lademirsen-for-alport-syndrome-301489408.html

    PRNEWSWIRE
    24 Feb 2022
    Share Share